Search results for "Statin"

showing 5 items of 545 documents

The effects of statins on blood pressure: current knowledge and future perspectives.

2012

statins blood pressure
researchProduct

Effects “beyond-cholesterol” of statins: simvastatin reduces the levels of atherogenic lipoproteins in patients with premature coronary artery disease

2002

statins simvastatin atherogenic lipoproteins coronary artery disease
researchProduct

Delayed and In-beam Spectroscopy on Francium and Astatine Nuclei at the Proton Drip Line

2011

Delayed and in‐beam spectroscopy on francium and astatine nuclei at and beyond the proton drip line has been performed. In neutron deficient astatine nuclei a shift to deformed shapes as a function of decreasing neutron has been obtained. In neutron deficient francium isotope the same shift is evident.

ta114ProtonIsotopeAstrophysics::High Energy Astrophysical PhenomenaNuclear TheoryHadronRadiochemistrychemistry.chemical_elementFranciumNuclear physicschemistryNeutronPhysics::Atomic PhysicsNuclear ExperimentSpectroscopyNucleonAstatineAIP Conference Proceedings
researchProduct

Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments

2021

Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation of cachexia, thus affecting quality of life and overall survival in cancer patients. Pre-clinical studies have shown that blocking activin receptor type 2 (ACVR2) or its ligands and their downstream signaling can preserve muscle mass in rodents bearing experimental cancers, as well as in chemotherapy-treated animals. In tumor-bearing mice, the prevention of skeletal and respiratory muscle wasting was also associated with improved survival. However, the definitive proof tha…

tumorCachexiaActivin ReceptorsActivin Receptors Type IIMyostatinReviewchemotherapymulti-organType IIsurvivalCachexiaNeoplasmsmedicineRespiratory muscleHumansActivins; Cancer cachexia; Chemotherapy; Mortality; Multi-organ; Muscle wasting; Myostatin; Survival; Tumor; Activin Receptors Type II; Cachexia; Humans; Neoplasms; Signal Transduction; Survival Analysislcsh:QH301-705.5Wastingsoluviestintäbiologysyöpähoidotbusiness.industryactivinsCancerSkeletal musclemuscle wastingGeneral MedicineActivin receptormedicine.diseaseSurvival AnalysismortalityBlockademedicine.anatomical_structurelcsh:Biology (General)myostatinCancer researchbiology.proteinproteiinitmedicine.symptombusinesshenkiinjääminenlihassurkastumasairaudetSignal Transductioncancer cachexia
researchProduct

Lipīdu profila raksturojums un to atbilstība vadlīniju mērķiem koronārās sirds slimības pacientiem, kas stacionēti Latvijas Kardioloģijas centrā

2018

Ievads: Kardiovaskulārās slimības (KVS) mirstības ziņā joprojām ieņem pirmo vietu pasaulē. Latvijā 2014. gadā tās veidoja 64% no visiem nāves cēloņiem sievietēm un 49% no visiem nāves cēloņiem vīriešiem (OECD, 2017). Jo īpaši, zema blīvuma lipoproteīnu holesterīns (ZBLH) ir galvenais terapeitiskais mērķis, aizkavējot saslimšanu ar KVS. Nesen papildinātās dislipidēmijas ārstēšanas vadlīnijas nosaka ļoti augsta riska pacientiem ZBLH mērķa līmeni <1,8 mmol/L un sākotnējā ZBLH līmeņa pazemināšanu vismaz par 50%. Mērķis: Analizēt lipīdu mērķa līmeņu sasniegšanas biežumu – ZBLH <1,8 mmol/L un ne - ABLH <2,6 mmol/L, un analizēt lipīdus pazeminošo līdzekļu (LPL) lietošanu starp pacientiem ar ļoti a…

very high-risk patientsCHDstatin therapyECS/EAS guidelinesLDL-CMedicīna
researchProduct